Chronic Lymphocytic Leukemia News

CHRONIC LYMPHOCYTIC LEUKEMIA ADVISOR

Chronic Lymphocytic Leukemia News

FDA-logo

FDA: Safety Concerns With Lymphoma Drug Ukoniq

An initial review of data from the phase 3 UNITY trial in CLL patients showed the combination of Ukoniq and ublituximab was associated with increased risk of death compared with the control arm.
Next post in Chronic Lymphocytic Leukemia News